China SXT Pharmaceuticals (SXTC) Long-Term Investments (2019 - 2022)

China SXT Pharmaceuticals' Long-Term Investments history runs 4 years deep, the most recent figure standing at $1.6 million for Q3 2022.

• In Q3 2022, Long-Term Investments changed 0.0% year-over-year to $1.6 million; the TTM figure through Sep 2022 stood at $1.6 million (changed 0.0% YoY), while the FY2022 annual figure was $1.6 million, changed 0.0% from the prior year.
• Long-Term Investments was $1.6 million for Q3 2022 at China SXT Pharmaceuticals, roughly flat from $1.6 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $1.6 million in Q3 2020 to a low of -$3.6 million in Q3 2019.
• Historically, Long-Term Investments has averaged $840764.9 across 4 years, with a median of $1.6 million in 2021.
• The sharpest annual moves came in 2020 and 2021: Long-Term Investments surged 144.49% in 2020, then retreated 1.68% in 2021.
• A 4-year view of Long-Term Investments shows it stood at -$3.6 million in 2019, then jumped by 144.49% to $1.6 million in 2020, then retreated by 1.68% to $1.6 million in 2021, then changed by 0.0% to $1.6 million in 2022.
• The last three Long-Term Investments figures came in at $1.6 million (Q3 2022), $1.6 million (Q1 2022), and $1.6 million (Q3 2021), per Business Quant data.